India, Aug. 9 -- QRL Bioscience, a cutting-edge biotechnology startup dedicated to developing personalised, cell-based therapies for chronic degenerative diseases, has raised Rs 3 crore in its latest funding round from GVFL, one of India's pioneering venture capital firms.

Founded initially with a vision to transform the treatment of (DFU) and Osteoarthritis, Ahmedabad-based QRL Bioscience is spearheading a new era of regenerative medicine in India.

The fresh capital infusion from GVFL will be utilised to accelerate the clinical trial phase of its DFU therapy and support the preclinical development of its osteoarthritis treatment.

QRL previously raised a seed fund from Tie India Angel investors. QRL Bioscience plans to deploy the capit...